QQQ   271.36 (+0.11%)
AAPL   446.83 (+1.49%)
MSFT   213.11 (+0.08%)
FB   262.01 (+5.17%)
GOOGL   1,491.50 (+0.84%)
AMZN   3,196.05 (-0.28%)
NVDA   449.52 (-0.43%)
CGC   18.29 (-4.79%)
BABA   260.50 (-1.66%)
TSLA   1,490.63 (+0.38%)
MU   48.86 (-4.31%)
GE   6.32 (-1.25%)
AMD   86.06 (+0.88%)
T   29.83 (-0.07%)
F   6.95 (-0.14%)
ACB   10.27 (-4.11%)
GILD   68.80 (-0.29%)
NFLX   503.90 (+0.36%)
DIS   127.47 (-0.11%)
BAC   25.46 (+0.28%)
BA   172.82 (-0.84%)
QQQ   271.36 (+0.11%)
AAPL   446.83 (+1.49%)
MSFT   213.11 (+0.08%)
FB   262.01 (+5.17%)
GOOGL   1,491.50 (+0.84%)
AMZN   3,196.05 (-0.28%)
NVDA   449.52 (-0.43%)
CGC   18.29 (-4.79%)
BABA   260.50 (-1.66%)
TSLA   1,490.63 (+0.38%)
MU   48.86 (-4.31%)
GE   6.32 (-1.25%)
AMD   86.06 (+0.88%)
T   29.83 (-0.07%)
F   6.95 (-0.14%)
ACB   10.27 (-4.11%)
GILD   68.80 (-0.29%)
NFLX   503.90 (+0.36%)
DIS   127.47 (-0.11%)
BAC   25.46 (+0.28%)
BA   172.82 (-0.84%)
QQQ   271.36 (+0.11%)
AAPL   446.83 (+1.49%)
MSFT   213.11 (+0.08%)
FB   262.01 (+5.17%)
GOOGL   1,491.50 (+0.84%)
AMZN   3,196.05 (-0.28%)
NVDA   449.52 (-0.43%)
CGC   18.29 (-4.79%)
BABA   260.50 (-1.66%)
TSLA   1,490.63 (+0.38%)
MU   48.86 (-4.31%)
GE   6.32 (-1.25%)
AMD   86.06 (+0.88%)
T   29.83 (-0.07%)
F   6.95 (-0.14%)
ACB   10.27 (-4.11%)
GILD   68.80 (-0.29%)
NFLX   503.90 (+0.36%)
DIS   127.47 (-0.11%)
BAC   25.46 (+0.28%)
BA   172.82 (-0.84%)
QQQ   271.36 (+0.11%)
AAPL   446.83 (+1.49%)
MSFT   213.11 (+0.08%)
FB   262.01 (+5.17%)
GOOGL   1,491.50 (+0.84%)
AMZN   3,196.05 (-0.28%)
NVDA   449.52 (-0.43%)
CGC   18.29 (-4.79%)
BABA   260.50 (-1.66%)
TSLA   1,490.63 (+0.38%)
MU   48.86 (-4.31%)
GE   6.32 (-1.25%)
AMD   86.06 (+0.88%)
T   29.83 (-0.07%)
F   6.95 (-0.14%)
ACB   10.27 (-4.11%)
GILD   68.80 (-0.29%)
NFLX   503.90 (+0.36%)
DIS   127.47 (-0.11%)
BAC   25.46 (+0.28%)
BA   172.82 (-0.84%)
Log in

NYSE:ZYMEZymeworks Stock Price, Forecast & News

$31.68
+0.41 (+1.31 %)
(As of 08/6/2020 12:14 PM ET)
Add
Compare
Today's Range
$30.63
Now: $31.68
$32.50
50-Day Range
$29.21
MA: $34.00
$40.00
52-Week Range
$20.33
Now: $31.68
$52.75
Volume10,204 shs
Average Volume471,721 shs
Market Capitalization$1.44 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.01
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Zymeworks logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.54 million
Book Value$6.24 per share

Profitability

Net Income$-145,440,000.00
Net Margins-629.37%

Miscellaneous

Employees180
Market Cap$1.44 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$31.68
+0.41 (+1.31 %)
(As of 08/6/2020 12:14 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock been impacted by COVID-19 (Coronavirus)?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ZYME shares have decreased by 2.4% and is now trading at $31.49.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Zymeworks?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zymeworks
.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Zymeworks
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.77) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.86) by $0.09. Zymeworks had a negative return on equity of 46.17% and a negative net margin of 629.37%.
View Zymeworks' earnings history
.

What price target have analysts set for ZYME?

12 brokerages have issued 12-month target prices for Zymeworks' stock. Their forecasts range from $42.00 to $70.00. On average, they anticipate Zymeworks' share price to reach $52.91 in the next year. This suggests a possible upside of 68.0% from the stock's current price.
View analysts' price targets for Zymeworks
.

Has Zymeworks been receiving favorable news coverage?

News coverage about ZYME stock has trended negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Zymeworks earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Zymeworks
.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Just Energy Group (JE), Just Energy Group (JE), Gilead Sciences (GILD), Cronos Group (CRON), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), AbbVie (ABBV) and Aurora Cannabis (ACB).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of institutional and retail investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.76%), Peregrine Capital Management LLC (0.44%), Raymond James & Associates (0.29%), Picton Mahoney Asset Management (0.26%), Swiss National Bank (0.17%) and Taylor Wealth Management Partners (0.15%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks
.

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Picton Mahoney Asset Management, Taylor Wealth Management Partners, UBS Group AG, Chartwell Investment Partners LLC, and Cornerstone Investment Partners LLC.
View insider buying and selling activity for Zymeworks
.

Which institutional investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Swiss National Bank, Moody Aldrich Partners LLC, Peregrine Capital Management LLC, SG Americas Securities LLC, Raymond James & Associates, Public Employees Retirement Association of Colorado, and Arizona State Retirement System. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $31.49.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.43 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 180 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.